Monday, 6 May 2024
  
Login

Australia's most trusted
source of pharma news

Monday, 06 May 2024
Listen to this story 
News

New hope for Roche's PD drug

Posted 23 April 2024 AM

Undeterred from a study flop, Roche's efforts in Parkinson's disease (PD) could finally pay off with re-analysis of the data showing its monoclonal antibody prasinezumab may slow disease in a subset of patients.

The original Phase 2 PASENDA found no meaningful effect on disease progression, however in a post hoc analysis the researchers split the data to analyse the drug's effect on slowly and rapidly progressing PD.

To see the whole article, please login

Popular

Fastest growing skills in pharma
Novartis exec nabs new role
Drug ready to take PBS throne
How big can this company get?
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (24)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (10)

Other (27)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home